利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.034 秒)

    SEMA5B PEPTIDES AND VACCINES CONTAINING THE SAME
    22.
    发明申请
    SEMA5B PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
    SEMA5B肽和含有它们的疫苗

    公开(公告)号：US20150322112A1

    公开(公告)日：2015-11-12

    申请号：US14648433

    申请日：2013-12-02

    申请人： ONCOTHERAPY SCIENCE, INC.

    发明人： Takuya TSUNODA ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： C07K7/06 ,  G01N33/50 ,  C07K16/18

    CPC分类号： C07K7/06 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/53 ,  C07K14/4703 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/34 ,  G01N33/505

    摘要： Peptide vaccines against cancer are described herein. Isolated epitope peptides derived from the SEMA5B gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The peptides encompass both SEMA5B-derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for use in cancer immunotherapy.

    摘要翻译： 本文描述了针对癌症的肽疫苗。 提供了衍生自引起CTL的SEMA5B基因并因此适用于癌症免疫治疗的上下文中的分离的表位肽。 肽包括SEMA5B衍生肽和其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持原始序列的必需的CTL诱导性。 还提供了编码这种肽的多核苷酸以及包括任何这样的肽或作为活性剂的多核苷酸的药物组合物。 还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。 此外，本发明提供了用于癌症免疫治疗的方法。

    WDRPUH Epitope Peptides and Vaccines Containing the Same
    23.
    发明申请
    WDRPUH Epitope Peptides and Vaccines Containing the Same 审中-公开
    WDRPUH表位肽和含有其的疫苗

    公开(公告)号：US20130315942A1

    公开(公告)日：2013-11-28

    申请号：US13900720

    申请日：2013-05-23

    申请人： OncoTherapy Science, Inc.

    发明人： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： C07K14/47 ,  C12N5/0783 ,  A61K38/17 ,  C12N5/0784

    CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K38/1764 ,  A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C12N5/0638 ,  C12N5/0639

    摘要： The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.

    摘要翻译： 本发明提供了含有SEQ ID NO：1,2,3,4，16，17，30，31，34，36，37，40，41，45，49，55，57和61的氨基酸序列的肽 ，以及含有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失，插入或添加，但仍具有细胞毒性T细胞诱导性。 本发明还提供了用于治疗或预防肿瘤的药物，其含有这些肽的药物。 本发明的肽也可以用作疫苗。

    Peptide Vaccines For Cancers Expressing Tumor-Associated Antigens
    24.
    发明申请
    Peptide Vaccines For Cancers Expressing Tumor-Associated Antigens 失效
    表达肿瘤相关抗原的癌症疫苗

    公开(公告)号：US20130189291A1

    公开(公告)日：2013-07-25

    申请号：US13744354

    申请日：2013-01-17

    申请人： Oncotherapy Science, Inc.

    发明人： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura

    IPC分类号： C07K7/06

    CPC分类号： C07K4/12 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/47 ,  G01N2500/00

    摘要： The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

    摘要翻译： 本发明提供了具有SEQ ID NO：19,22,30,34,344,358,41,44,46,48,78,376,49,48,78,376,479,48和78的氨基酸序列的肽。 110,111,387,112,394,114,116,117,121,345,133,135,137,426,143,147,148,149,150,152,153,154,156,160,161， 162,163,166,174,178,186,194,196,202,210,213,214,217,223,227,228,233,254,271,272或288以及具有上述的肽的肽， 提供其中1,2或几个（例如，至多5个）氨基酸被取代，缺失或添加的上述氨基酸序列，条件是肽具有细胞毒性T细胞诱导性。 本发明还提供用于治疗或预防与CDH3，EPHA4，ECT2，HIG2，INHBB，KIF20A，KNTC2，TTK和/或URLC10的过表达相关的疾病的药物，例如。 含有这些肽中的一种或多种的活性成分的癌症。 本发明的肽可作为疫苗进一步发挥作用。